Case Report 2
Ms B is hispanic and aged 37 years. She has a history of dysthymic disorder and was referred to her internist to confirm a diagnosis of fibromyalgia. She had not been able to tolerate bupropion for her dysthymic disorder but had done well on escitalopram 10 mg daily. Her internist started her on amitriptyline 50 mg daily and methocarbamol 1 g 4 times daily as needed for pain. She discontinued the amitriptyline after 2 weeks, complaining of excessive sedation and dry mouth. She had no other medical problems and did not use tobacco, alcohol, or illicit substances. Her laboratory examination was within normal limits on a complete blood count, comprehensive metabolic panel, liver enzymes, thyroid-stimulating hormone, erythrocyte sedimentation rate, lyme titer, and urinalysis; her human chorionic gonadotropin was negative. Her main concerns were ongoing multiple tender points and daily fatigue. She gave informed consent to a trial of atomoxetine to target her symptoms and was started at 40 mg daily, increased at 2 weeks' time to 80 mg and titrated to 120 mg daily at 1 month's time. She has maintained her marked improvement at 6 months and is working full-time.
Antidepressants are commonly used to treat fibromyalgia. Because the pain associated with fibromyalgia tends to be more centrally than peripherally mediated, medications that raise central levels of norepinephrine are most effective (5) . In the treatment of FMS, use of amitriptyline has been best documented (6) . Venlafaxine, an SNRI, has also been used to treat FMS (4, 7, 8) . SSRIs used alone do not seem to be effective (6). In the cases described, the patients were taking an SSRI, and their mood disorders were in remission; however, they were experiencing symptoms associated with their fibromyalgia. Instead of switching classes of medication, atomoxetine was added to their regimen. It was chosen because it is a norepinephrine reuptake inhibitor (approved for the treatment of attention-deficit hyperactivity disorder, 9) . Although the addition of atomoxetine to existing SSRIs shows promising outcomes in treating FMS, further, more controlled studies are warranted. Additionally, we recommend that physicians prescribing atomoxetine for off-label use appropriately document informed consent weighing both the risks and the benefits, compared with agents that are already FDA-approved for the particular condition. In the case of fibromyalgia, where there is no particular FDA-approved agent, it is important to compare it with agents that have been most widely used in the treatment of fibromyalgia.
Tim Berigan, DDS, MD Vail, Arizona

Re: Autism-Its Detection, Causes, and Treatment
Dear Editor: I welcome the reviews of autism in the September 2003 issue of the CJP. I was a little saddened that there was no reference to the research I have conducted, but not surprised. After all, I concluded that the "pathology" of autism is not an illness or deficit but, rather, a condition of being extra sensitive. It is less a case of autism sufferers being abnormal in a normal environment than it is of their being supernormal in an abnormal environment. Tinbergen, Wing, and Rimland (personal communication) thought the findings and treatment I described were quite useful. Further, I have had the unique opportunity to help establish autistic societies in 5 cities in 4 countries and also to set up 4 treatment programs for autism. As did the authors contributing to the September 2003
In Review section, I found very few, if any, abnormalities after conducting behavioural, physiological, and psychological research. I chuckle a little at the air of confidence expressed by those authors who indicate they are quite sure autism is a genetic disorder that alters neurology and expresses itself in terms of affective and communication abnormalities: no one has found much to support these conclusions. Although there are a "few consistently identified biological abnormalities in autism" and "no single environmental risk factor has been shown" (1), the authors are sure they are on the right track and sure they will find something in the near future.
Why, when there is increasing evidence that the plastic brain of an infant is moulded by experience, particularly emotionally charged experience, is this not considered? More particularly, why isn't the possibility consisdered that autism is not an abnormality but a variation of the brain that puts the child at risk in the average, but not necessarily normal, environment. I believe most, if not all, symptoms shown by an autistic child can be explained by the child's auditory hyperacuity. Our research was able to establish that, given an opportunity, autistic children are very keen to control the level of sound in their environment (2) (3) (4) (5) . This accords with their parents' accounts of their children being extremely responsive to distant sirens when no one else in the family (apart from, possibly, household animals) could hear the sound. We found the auditory evoked potentials to be quite unusual in autistic children-larger and faster, but not necessarily abnormal. Additionally, the typical autistic child is very good looking. That is partly what creates such deep dilemmas for the parents. Can anybody think of a single genetic disorder that leaves the child looking more, rather than less, beautiful? I can't.
